| About ParaGard® |
| Product Description Why ParaGard® Patient Types ParaGard® Resources (PDFs) Reimbursement Test Your Knowledge Patient FAQs HCP FAQs |
| HCP Resources |
| ParaGard® Resources (PDFs) Resource Request Request a Representative Online Learnings Scientific Highlights HCP FAQs |
| Insertion Training |
| Insertion Process Insertion Process Video |
| How to Order |
| Ways to Order ParaGard® ParaGard® Direct Description ParaGard® Direct Cost Estimator |
| Recommending ParaGard® |
| Contraceptive Counseling ParaGard® Candidates ParaGard® Patients Patient Product Information |
| Procurement Information |
| Reimbursement Ordering Payment Options |
| Resources For Your Patients |
| Resource Overview Patient Translation Materials Cost Estimator Patient Product Information Patient FAQs Payment Options Overview |
| Reimbursement |
| Reimbursement Q&A |
ParaGard® does not protect against HIV/AIDS or other sexually transmitted infections. ParaGard® must not be used by women who are or may be pregnant; have acute pelvic inflammatory disease (PID) or current behavior suggesting a high risk for PID; have had a postpregnancy or postabortion uterine infection in the past 3 months; have cancer of the uterus or cervix; have an infection in the cervix; have an allergy to any component; or have Wilson's disease. The most common side effects of ParaGard® are heavier and longer periods and spotting between periods; for most women, these typically subside after 2 to 3 months. If a woman misses her period, she must be promptly evaluated for pregnancy. Some possible serious complications that have been associated with intrauterine contraceptives, including ParaGard®, are PID, perforation of the uterus, and expulsion.
ParaGard® is a registered trademark of Duramed Pharmaceuticals, Inc.
©2009 Duramed Pharmaceuticals, Inc.